Go Deep
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,080 | -10.0 | 5.03 | 0.04 | 3,274.13 |
| Oct 2026 | 18,104 | -10.0 | 5.01 | 0.04 | 3,251.00 |
| Oct 2026 | 18,101 | -10.0 | 5.01 | 0.04 | 3,253.37 |
| Oct 2026 | 18,477 | -9.4 | 4.70 | 0.04 | 3,040.35 |
| Oct 2026 | 18,325 | -9.6 | 4.82 | 0.04 | 3,126.10 |
| Oct 2026 | 17,956 | -10.2 | 5.13 | 0.04 | 3,327.11 |
| Oct 2026 | 17,887 | -10.3 | 5.19 | 0.04 | 3,356.72 |
| Oct 2026 | 17,798 | -10.5 | 5.26 | 0.04 | 3,398.07 |
| Oct 2026 | 17,855 | -10.4 | 5.22 | 0.04 | 3,380.88 |
Definium Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -158,986,000.0 | -77,098,000.0 | -50,436,000.0 | -67,265,000.0 |
| EPS | -1.4 | -0.7 | — | -0.8 |
Definium Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -183,793,000.0 | -108,679,000.0 | -95,732,000.0 | -56,796,000.0 | — |
| EPS | -2.1 | -1.5 | -2.4 | -1.8 | — |
Definium Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 440,100,000.0 | 302,151,000.0 | 124,541,000.0 | 169,993,000.0 | — |
| Total Liabilities | 107,773,000.0 | 60,703,000.0 | 46,407,000.0 | 19,076,000.0 | — |
| Total Equity | 332,327,000.0 | 241,448,000.0 | 78,134,000.0 | 150,917,000.0 | — |
Owes vs Owns
Definium Therapeutics, Inc. owed $0.17 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.24× | 0.20× | 0.37× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Definium Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.5%Intangible assets 4.5%Other assets 2.0%
How it's funded — Dec 2025
Long-term debt 9.2%Payables 1.2%Other liabilities 14.1%Shareholders' equity 75.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 411.6 | 273.7 | 99.7 | 142.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 19.9 | 19.9 | 20.4 | 23.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 8.6 | 8.5 | 4.4 | 4.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 40.6 | 21.9 | 14.1 | 0.0 |
| Payables | 5.3 | 2.0 | 4.1 | 2.1 |
| Other liabilities | 61.8 | 36.8 | 28.1 | 16.9 |
| Shareholders' equity | 332.3 | 241.4 | 78.1 | 150.9 |
| Net tangible assets | 312.4 | 221.5 | 57.7 | 127.3 |
Definium Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -131,560,000.0 | -79,129,000.0 | -64,365,000.0 | -50,139,000.0 | — |
| Investing Activities | -151,606,000.0 | 0.0 | — | 0.0 | -297,000.0 |
| Financing Activities | 267,269,000.0 | 253,196,000.0 | 21,848,000.0 | 59,051,000.0 | — |